CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial Novel percutaneous interventional therapies in heart failure with preserved ejection fraction: an integrative review Nitrosative stress drives heart failure with preserved ejection fraction Can We Use the Intrinsic Left Ventricular Delay (QLV) to Optimize the Pacing Configuration for Cardiac Resynchronization Therapy With a Quadripolar Left Ventricular Lead? Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk of Heart Failure Heart Failure With Preserved Ejection Fraction in the Young HFpEF: From Mechanisms to Therapies Functional Impairment and Medication Burden in Adults With Heart Failure

Clinical Trial21 (12), 1596-1604

JOURNAL:Eur J Heart Fail. Article Link

Baseline Features of the VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) Trial

B Pieske, MJ Patel, VICTORIA Study Group et al. Keywords: cyclic guanosine monophosphate; HFrEF; soluble guanylate cyclase

FULL TEXT PDF